Precision Business Insights
Portfolio

 

Research Reports

Hyperprolactinemia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Global Hyperprolactinemia Treatment Market: By Drug Type (Dopamine Agonists (Cabergoline, Bromocryptine, Lisuride, Quinagolide, Terguride)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Hyperprolactinemia Treatment Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 

Market Dynamics: Hyperprolactinemia Treatment Market

 

Hyperprolactinemia is the disease characterized by presence of high levels of prolactin in blood. Prolactin is secreted by anterior pituitary gland. It is primarily associated with lactation and helps in the breast development during pregnancy. Hyperprolactinemia may cause the galactorrhea, disruptions in the menstrual cycle in women, and erectile dysfunction in men. Increase in the usage of dopamine-blocking drugs such as antipsychotics and dopamine synthesis inhibitors, rise in R&D for the synthesis of newer hyperprolactinemia treatment drugs, increase in the prevalence of chronic renal failure and epileptic seizures, and rise in healthcare expenditure are anticipated to fuel the hyperprolactinemia treatment market over the forecast period. However, stringent regulatory policies for product approval, limited number of treatment options, adverse effects associated with available drugs, and lack of awareness about hyperprolactinemia among healthcare professionals in underdeveloped countries may restrain the growth of hyperprolactinemia market over the future years.

 

Market Scope: Hyperprolactinemia Treatment Market

Hyperprolactinemia treatment market is segmented on the basis of drug type, distribution channel, and region

Based on the drug type, the market is segmented into the following:

  • Dopamine Agonists
    • Cabergoline
    • Bromocryptine
    • Lisuride
    • Quinagolide
    • Terguride

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on the region, the market is segmented into the following:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Regional Analysis:  Hyperprolactinemia Treatment Market

Geographically, global hyperprolactinemia market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America hyperprolactinemia treatment market growth driven by increase in the R&D for the innovation of newer drugs, rise in healthcare expenditure, and increase in the usage of antipsychotics. Europe hyperprolactinemia treatment market is poised to grow at significant rate due to rise in awareness about hyperprolactinemia treatment among healthcare professionals, accessibility of drugs, and increase in the usage of anti-hypertensive drugs such as calcium channel drugs are expected to propel the market.

 

Competition Assessment: Hyperprolactinemia Treatment Market

Key players profiles in the global hyperprolactinemia market include:

  • GlaxoSmithKline Plc (U.K.)
  • Novartis AG (Switzerland)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Zydus Takeda Healthcare Pvt. Ltd. (India)
  • Mylan N.V. (U.S.)

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • GlaxoSmithKline Plc (U.K.)
  • Novartis AG (Switzerland)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Zydus Takeda Healthcare Pvt. Ltd. (India)
  • Mylan N.V. (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials